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Abstract
Introduction—Polypharmacy, defined as the use of multiple drugs or more than are medically
necessary, is a growing concern for older adults.
Areas Covered—We present information about; 1.) Prevalence of polypharmacy and
unnecessary medication use. ; 2.) Negative Consequences of Polypharmacy; 3.) Interventions to
improve polypharmacy.
Expert Opinion—International research shows that polypharmacy is common in older adults
with the highest number of drugs taken by those residing in nursing homes. Nearly 50% of older
adults take one or more medications that are not medically necessary. Research has clearly
established a strong relationship between polypharmacy and negative clinical consequences.
Moreover, well designed inter-professional (often incuding clinical pharmacist) intervention
studies that focus on enrolling high risk older patients with polypharmacy have shown that they
can be effective in improving the overall quality of prescribing with mixed results on distal health
outcomes.
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1.0 Introduction
Given the rising tide of persons over the age of 65 worldwide, polypharmacy is a becoming
more prevalent in older adults. Examining the definition as it appears in a standard medical
dictionary reveals that the word “poly” is derived from the Greek word meaning more than
one and that “pharmacy” referring to the Greek word for drug “pharmacon”[1].
Unfortunately, there is no standard cut point with regard to the number of medications that is
agreed upon for the definition of polypharmacy. To operationalize this definition,
researchers have arbitrarily chosen various cut points. An alternative definition for
polypharmacy is the use of more medications than are medically necessary [2]. For this
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definition, medications that are not indicated, not effective, or constitute a therapeutic
duplication would be considered polypharmacy. Although this definition is more clinically
relevant, it does necessitate a clinical review of medication regimens.
This review will begin with information about the prevalence and types of medications taken
by older adults with polypharmacy. This section will also highlight the prevalence and types
of unnecessary drugs as well. The next section will detail the epidemiology of adverse health
outcomes resulting from polypharmacy. Following this, evidence from randomized,
controlled intervention trials that included older adults with polypharmacy showing how
medication use can be improved will be presented. We will then finish with an expert
opinion and conclusion sections.
2.0 Polypharmacy in the Various Settings (Table 1)
There have been numerous studies that have documented the rates of polypharmacy defined
as multiple drugs in various settings. Fewer studies have focused on the use of unnecessary
drugs.
2.1 Ambulatory Care
Many studies in ambulatory care define polypharmacy as a medication count of five or more
medications. However, current medical practice guidelines often require multiple
medications to treat each chronic disease state for optimal clinical benefit. Therefore, an
elderly patient with at least two disease states, such as heart failure and chronic obstructive
pulmonary disease, will usually exceed this arbitrary threshold of > five medications [3]. For
example, a 2005-2006 study from the USA reported by Qato et al used a population-based
survey of community dwelling persons 57-85 years of age [4]. Overall 37.1% of men and
36% of women between 75 and 85 years of age took at least five prescription medications.
Table 1 shows the most common prescription medications reported. Moreover, among this
older age group taking at least one prescription medication, 47.3% reported the use of an
over-the-counter medication and 54.2% a dietary supplement. The use of unnecessary drugs
was studied in 128 older male outpatients from the United States [5]. Overall 58.6% of
patients took one or more unnecessary prescribed drug. The most commonly prescribed
unnecessary drugs are summarized in Table 1.
2.2 Hospital Setting
Few studies have examined the issue of polypharmacy in the hospitalized elders. A study by
Hajjar and colleagues looked at both definitions of polypharmacy at hospital discharge [6].
Among 384 patients studied, it was reported that 41.4 % were on at least 5-8 medications,
and 37.2% were on 9 or more. Overall 58.6% of patients took one or more unnecessary
prescribed drug. Table 1 lists the most common unnecessary medication classes and
individual agents. An Italian study in 2011, examined the prevalence of polypharmacy in the
hospital setting both at admission and discharge [7]. They found that on admission 51.9% of
patients were on greater than five medications with an average of 4.9 medications and 5.2
diagnoses. At discharge this rate increased to 67% with an average of 6.0 medications and
5.9 diagnoses. Table 1 provides information about the most common drug classes that
patients were on at discharge.
2.3 Nursing Home Setting
Polypharmacy in nursing homes has been an ongoing concern over the past four decades. In
the late 1990's, the US Center of Medicare and Medicaid Services felt this to be such an
important issue that it implemented a quality indicator measure targeting patients on 9 or
more medications. A study using data from the 2004 United States Nursing Home Survey
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found that 39.7% had polypharmacy defined by this quality indicator measure [8]. Of note
the group with the lowest rate of polypharmacy was those patients age 85 years or older
(34.8%). Table 1 shows the top ten most common medication classes used among this
nursing home population. In contrast, a study of 64,395 Canadian nursing home patients
studied reported that only 15.5% were on > 9 medications [9]. The top therapeutic drug
classes prescribed to this cohort can be seen in Table 1. To the best of our knowledge no
multisite study has been conducted examining unnecessary drug use in older nursing home
patients [2].
3.0 Consequences of Polypharmacy
Unfortunately, there are many negative consequences associated with polypharmacy. ,
Specifically, the burden of taking multiple medications has been associated with greater
health care costs and an increased risk of adverse drug events (ADEs), drug-interactions,
medication non-adherence, reduced functional capacity and multiple geriatric syndromes.
3.1 Increased Healthcare Costs
Polypharmacy contributes to health care costs to both the patient and the healthcare system.
A retrospective cohort study found that polypharmacy was associated with an increased risk
of taking a potentially inappropriate medication and an increased risk of outpatient visits,
and hospitalization with an approximate 30% increase in medical costs [10]. Another study
conducted in Sweden reported that those taking 5 or more medications had a 6.2% increase
in prescription drug expenditure and those taking 10 or more medications had a 7.3%
increase [11].
3.2 Adverse Drug Events
In 2005, it was estimated that over 4.3 million health care visits were attributed to an ADE
[12]. It has been reported that up to 35% of outpatients and 40% of hospitalized elderly
experience an ADE. Furthermore, approximately 10% of emergency room visits are
attributed to an ADE [13]. In a population based study, outpatients taking 5 or more
medications had an 88% increased risk of experiencing an ADE compared to those who
were taking fewer medications [12]. In nursing home residents, rates of ADEs have been
noted to be twice as high in patients taking 9 or more medications compared to those taking
less [14]. Another study evaluating unplanned hospitalizations in older veterans found that a
patient taking more than 5 medications was almost 4 times as likely to be hospitalized from
ADE [15]. As one might expect, common drug classes associated with ADEs include
anticoagulants, NSAIDs, cardiovascular medications, diuretics, antibiotics, anticonvulsants,
benzodiazepines, and hypoglycemic medications [13,15,16].
3.3 Drug-Interactions
Older adults with polypharmacy are predisposed to drug- interactions [17]. In a prospective
cohort study of older hospitalized adults taking 5 or more medications, the prevalence of a
potential hepatic cytochrome enzyme-mediated, drug-drug interaction was 80%. The
probability of a drug-drug interaction increased with the number of medications.
Specifically, a patient taking 5-9 medications had a 50% probability whereas the risk
increased to 100% when a patient was found to be taking 20 or more medications [18]. In a
study of community-dwelling elderly adults, almost 50% of patients had a potential drug-
drug interaction [19]. Drug-drug interactions are a frequent cause of preventable ADEs and
medication-related hospitalizations [16,20]. , Thus practitioners should keep the possibility
of a drug-drug interaction in mind when prescribing any new medications.
Maher et al. Page 3
Expert Opin Drug Saf. Author manuscript; available in PMC 2014 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Studies have reported the prevalence of drug-disease interactions to be 15-40% in frail
elderly patients. Risk of drug-disease interactions has been shown to increase with increased
numbers of medications [21,22]. With patients living longer with more chronic disease
states requiring drug therapy, the risk of drug-disease interactions should be a concern for
healthcare providers.
3.4 Medication Non-adherence
Non-adherence with drugs in older adults has been associated with complicated medication
regimens and polypharmacy [23-27]. Non-adherence rates in community dwelling elderly
adults has been reported to be between 43-100% [24,25]. The large variance in the non-
adherence rates may be attributed to different methods, tools, and thresholds for categorizing
adherence as well as the variety of populations studied. In one study, the rate of patient non-
adherence was 35% when a patient was taking 4 or more medications [28]. Medication non-
adherence is associated with potential disease progression, treatment failure, hospitalization,
and ADEs, all of which could be life-threatening [24,27,28].
3.5 Functional Status
Polypharmacy has been associated with functional decline in older patients. In a prospective
study of community-dwelling older adults, increased prescription medication use was
associated with diminished ability to perform instrumental activities of daily living (IADLs)
and decreased physical functioning [29]. A study using data from the conducted aWomen's
Health and Aging Study, found that use of 5 or more medication was associated with a
reduced ability to perform IADLs [30]. A prospective cohort of approximately 300 older
adults found that patients taking 10 or more medications had diminished functional capacity
and trouble performing daily tasks [31]. As part of the Women's Health Initiative
Observational study, polypharmacy was associated with incident disability in older women
[32]. In patients who have reported falling in the past year, higher medication use was found
to be associated with functional decline [33]. Prescribers should be aware of the risk of
functional decline in patients taking multiple medications.
3.6 Cognitive Impairment
Cognitive impairment, seen with both delirium and dementia, has been associated with
polypharmacy. A study in hospitalized older adults reported that the number of medications
was a risk factor for delirium [34]. In a prospective cohort study of 294 elders, 22% percent
of patients taking 5 or less medications were found to have impaired cognition as opposed to
33% of patients taking 6-9 medications and 54% in patients taking 10 or more medications
[31].
3.7 Falls
Falls are associated with increased morbidity and mortality in older adults and may be
precipitated by certain medications. A study comparing patients who have not fallen
compared to those who have fallen once and those multiple times , reported that the number
of medications was associated with an increased risk of falls [35]. A study in older adult
outpatients asas the number of medications increased, the falls risk index score increased
and the duration of the one-leg standing test duration decreased [36]. In a prospective cohort
study, the use of 4 or more medications was associated with increased risk of falling and the
risk of recurrent falls [37]. A study in elderly patients with dementia reported that those
patients who reported a fall had an increased prevalence of polypharmacy [38]. In a study of
institutionalized older adults the risk of experiencing a fall within the previous 30 days was
by 7% for each additional medication [39]. Given the serious consequences of falls in older
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adults, caution should be used in prescribing new medications to those who are at risk of
falling.
3.8 Urinary Incontinence
Urinary incontinence is yet another problem that is associated with the use of multiple
medications. In a population-based, longitudinal study of women aged 70 years and older,
polypharmacy was associated with an increased risk of lower urinary tract symptoms [40].
Many medications are known to exacerbate urinary incontinence, so a medication review
should be performed to evaluate both the number of medications as well as the specific types
of medications a patient is taking.
3.9 Nutrition
Polypharmacy has also been reported to affect a patient's nutritional status. A prospective
cohort study found that 50% of those taking 10 or more medications were found to be
malnourished or at risk of malnourishment [31]. A survey of community-dwelling elders
older adults found that polypharmacy was associated with a reduced intake of fiber, fat-
soluble and B vitamins, and minerals as well as an increased intake of cholesterol, glucose,
and sodium [41].
4.0 Evidence that Unnecessary Drug Use Can Be Improved
Recently a comprehensive review was published on this subject [2]. They included 36
studies of which 15 were randomized controlled trials (RCTs). Only two RCTs measured
unnecessary drug use as defined by a valid implicit measure (i.e., 3 items from the MAI)
[42,43]. The study by Schmader et al included 430 frail hospitalized patients in the Geriatric
Evaluation and Management (GEM) care intervention group and 404 frail patients were in
the control group [42]. On average those inpatients randomized to the intervention group
took 10.4 medications which was similar to the 10.2 medications randomized to the control
group. The number of unnecessary medications taken by the intervention group at hospital
discharge was significantly reduced in comparison to those in control group patients (-0.5 vs
0.1). Another randomized controlled trial by Spinewine et al. examined the value of adding a
clinical pharmacist to an inpatient GEM team care had on unnecessary drug use [43]. The
sample consisted of 186 patients aged 70+ years of age. The rate of decline in patients with
unnecessary drug use was greater in the intervention vs the control group (46.9% vs 6.6%).
4.1 Evidence that Polypharmacy Can be Improved (Table 2)
There have been several comprehensive reviews that have summarized the data regarding
the quality of prescribing for older adults enrolled randomized controlled trials receiving
various interventions in different settings because they were taking multiple medications
[23,44-47]. Overall these reviews highlighted data from 50 studies of which only 5 were
included in two or more reviews [42,49-51]. Table 2 summarizes these five studies. As
shown, three studies were conducted in ambulatory care setting whereas the other two
studies were focused in long term care facilities. Three interventions were delivered by a
pharmacist and a multidisciplinary approach was used by the remaining two studies. A
statistically significant improvement was seen in the four studies that used the Medication
Appropriateness Index as a process measure [42,48,50,51. Only one study showed an
reduction in the use of ineffective medications [49]. While three studies measured ADEs,
only one showed a statistically significant reduction in serious ADEs ;42, 48, 50]. Only one
study showed an improvement in pain [50].
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5.0 Expert Opinion
Key research findings to date are that the percentage of older adults with polypharmacy
defined by medication count varies across numerous studies and health care settings. There
are few studies that have used a validated implicit measure of unnecessary drug use and
examined it's predictive validity with important health outcomes. In contrast, research has
clearly established a strong relationship between polypharmacy and negative clinical
consequences. Moreover, well designed inter-professional intervention studies that focus on
enrolling high risk older patients with polypharmacy have shown that they can be effective
in improving the overall quality of prescribing with mixed results on distal health outcomes.
In the coming years it is hopeful that increased research funding will become available for
the study of new and innovative interventions to reduce unnecessary drug use. . Further
research work is also needed in those patients with extreme polypharmacy (e.g., 20 or more
medications) since this phenomena should become more common due to greater numbers of
older adults with multiple co-morbid conditions and the discoveries of novel drug therapies.
6.0 Conclusion
Polypharmacy has been and always will be common among the elderly population due to the
need to treat the various disease states that develop as a patient ages. Unfortunately with this
increase in the use of multiple medications comes with an increased risk for negative health
outcomes such as higher healthcare costs, ADEs, drug-interactions, medication non-
adherence, decreased functional status and geriatric syndromes. More implementation
studies are needed to show that practical application of the methods shown to improve
polypharmacy issues can be disseminated to the various medical settings where older adults
receive care.
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Article Highlights Box
• Polypharmacy is defined as increase in the number of medications or the use of
more medications than are medically necessary.
• Polypharmacy is common in older ambulatory care, hospital, and nursing home
patients
• Polypharmacy increases the risk of numerous negative health consequences in
the elderly.
• The best intervention (s) for improving polypharmacy involves an inter-
professional approach that often includes a clinical pharmacist.
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Table 1
Summary of Observational Studies of Polypharmacy in Older Adults
Author/Year Setting/Country/Sample Polypharmacy Results Most Common Types of Medication
Class/Individual Medications
Qato 2008 Ambulatory/USA/N=2976 37.1% men and 36% women aged 75+
used at least 5 RX medications;
46% took an OTC medication and 52%
dietary supplements
hydrochlorthiazide, atorvastatin,
levothyroxine, lisinopril, metoprolol,
simvastatin, atenolol, amlodipine,
metformin, furosemide
Rossi, 2007 Ambulatory/USA/ N=128 58.6% took 1+ unnecessary drugs central nervous system, gastrointestinal,
vitamins
Hajjar 2005 Hospital/USA/n=384 37.2% ≥ 9 drugs 41.4% 5-8 drugs 21.4%
1-4 drugs;
58.6% took 1+ unnecessary drugs
gastrointestinal, central nervous system,
and therapeutic nutrients/minerals
H2 blockers, laxatives, genitourinary
antispasmodics, tricyclic antidepressants
Nobili , 2011 Hospital/Italy/n=1332 Admission-51.9% on 5+;
Discharge-67% on 5+
antithrombotics, gastrointestinal diuretics,
acei, beta-blockers, lipid and non-insulin
glucose lowering rxs, digoxin
Dwyer , 2009 Nursing Home/USA/N= 13,507 39.7% on 9+ meds laxatives, acid/peptic disorders,
antidepressants, antipsychotics/antimanics,
non-narcotic pain relievers, antipyretics,
antiarthritics
Bronskill, 2012 Nursing Home/Canada/n=64,395 15.5% on 9+ medications diuretics, ppi, aceI, beta-blockers,
benzodiazepines, ssris, ccb,
antipsychotics, statins, opioids
Abbreviations- acei(ACE Inhibitors), ccb(Calcium Channel Blockers), otc(Over-the-Counter Products), ppi(Proton Pump Inhibitors),
rx(prescriptions), ssri(Selective Serotonin Reuptake Inhibitors)
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